WallStreetZenWallStreetZen

NASDAQ: AIRS
Airsculpt Technologies Inc Stock Forecast, Predictions & Price Target

Analyst price target for AIRS

Based on 3 analysts offering 12 month price targets for Airsculpt Technologies Inc.
Min Forecast
$6.00+6.76%
Avg Forecast
$8.00+42.35%
Max Forecast
$10.00+77.94%

Should I buy or sell AIRS stock?

Based on 3 analysts offering ratings for Airsculpt Technologies Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AIRS stock forecasts and price targets.

AIRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Morgan Stanley
Bottom 1%
1
HoldMaintains$6.00+6.76%2023-01-17
Raymond James
Top 15%
86
BuyMaintains$10.00+77.94%2022-11-14
SVB Leerink
Top 20%
81
BuyMaintains$8.00+42.35%2022-11-14

1 of 1

Forecast return on equity

Is AIRS forecast to generate an efficient return?
Company
N/A
Industry
-0.01%
Market
12.46%

Forecast return on assets

Is AIRS forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.01%

AIRS earnings per share forecast

What is AIRS's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$0.34
Avg 2 year Forecast
$0.62
Avg 3 year Forecast
$0.96

AIRS revenue forecast

What is AIRS's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$220.8M+33.31%
Avg 2 year Forecast
$258.4M+55.97%
Avg 3 year Forecast
$302.5M+82.64%
AIRS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AIRS revenue growth forecast

How is AIRS forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
21.98%
Industry
9.93%
Market
9.31%
AIRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AIRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AIRS vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
AIRS$5.62$8.00+42.35%Buy
PIII$1.31N/AN/AStrong Buy
BTMD$4.16$10.00+140.38%Strong Buy
JYNT$18.70$27.25+45.72%Buy
PNTG$12.28$17.60+43.32%Hold

Airsculpt Technologies Stock Forecast FAQ

Is Airsculpt Technologies Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AIRS) stock is to Buy AIRS stock.

Out of 3 analysts, 0 (0%) are recommending AIRS as a Strong Buy, 2 (66.67%) are recommending AIRS as a Buy, 1 (33.33%) are recommending AIRS as a Hold, 0 (0%) are recommending AIRS as a Sell, and 0 (0%) are recommending AIRS as a Strong Sell.

If you're new to stock investing, here's how to buy Airsculpt Technologies stock.

What is AIRS's earnings growth forecast for 2023-2025?

(NASDAQ: AIRS) Airsculpt Technologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of 13.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 24.23%.

Airsculpt Technologies's earnings in 2023 is -$21,638,000.On average, 3 Wall Street analysts forecast AIRS's earnings for 2023 to be $19,098,632, with the lowest AIRS earnings forecast at $6,740,694, and the highest AIRS earnings forecast at $25,839,326. On average, 3 Wall Street analysts forecast AIRS's earnings for 2024 to be $34,826,917, with the lowest AIRS earnings forecast at $16,290,010, and the highest AIRS earnings forecast at $44,937,958.

In 2025, AIRS is forecast to generate $53,925,549 in earnings, with the lowest earnings forecast at $45,499,682 and the highest earnings forecast at $62,351,416.

What is AIRS's revenue growth forecast for 2023-2025?

(NASDAQ: AIRS) Airsculpt Technologies's forecast annual revenue growth rate of 21.98% is forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 9.93%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Airsculpt Technologies's revenue in 2023 is $165,646,000.On average, 4 Wall Street analysts forecast AIRS's revenue for 2023 to be $12,403,831,229, with the lowest AIRS revenue forecast at $11,950,182,547, and the highest AIRS revenue forecast at $12,796,083,427. On average, 4 Wall Street analysts forecast AIRS's revenue for 2024 to be $14,512,432,545, with the lowest AIRS revenue forecast at $13,956,606,182, and the highest AIRS revenue forecast at $14,902,550,189.

In 2025, AIRS is forecast to generate $16,994,131,253 in revenue, with the lowest revenue forecast at $16,627,044,312 and the highest revenue forecast at $17,361,218,194.

What is AIRS's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: AIRS) forecast ROA is N/A, which is lower than the forecast US Medical Care Facilities industry average of -0.01%.

What is AIRS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AIRS price target, the average AIRS price target is $8.00, with the highest AIRS stock price forecast at $10.00 and the lowest AIRS stock price forecast at $6.00.

On average, Wall Street analysts predict that Airsculpt Technologies's share price could reach $8.00 by Jan 17, 2024. The average Airsculpt Technologies stock price prediction forecasts a potential upside of 42.35% from the current AIRS share price of $5.62.

What is AIRS's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: AIRS) Airsculpt Technologies's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that AIRS's EPS will be $0.34 for 2023, with the lowest EPS forecast at $0.12, and the highest EPS forecast at $0.46. On average, analysts forecast that AIRS's EPS will be $0.62 for 2024, with the lowest EPS forecast at $0.29, and the highest EPS forecast at $0.80. In 2025, AIRS's EPS is forecast to hit $0.96 (min: $0.81, max: $1.11).

What is AIRS's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: AIRS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.